Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lau

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 1, 2011
A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damageSheng-Jia Zhang, Bettina Buchthal, David Lau, et al.
Journal of Virology|June 6, 2008
Competition model for upregulation of the major histocompatibility complex class II-associated invariant chain by human immunodeficiency virus type 1 NefRichard S Mitchell, Rittik Chaudhuri, O Wolf Lindwasser, et al.
Neurobiology of Disease|November 22, 2023
Activin A targets extrasynaptic NMDA receptors to ameliorate neuronal and behavioral deficits in a mouse model of Huntington diseaseWissam B Nassrallah, Daniel Ramandi, Judy Cheng, et al.
Plos Genetics|August 15, 2009
Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activitySheng-Jia Zhang, Ming Zou, Li Lu, et al.
The Journal of Headache and Pain|November 25, 2025
Uncovering the neurological substrates underlying restlessness in cluster headache - A functional MRI studyShu-Ting Chen, Chia-Chun Chiang, Yung-Lin Chen, et al.
Drugs in R&D|January 8, 2016
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical StudiesPaul Martin, Michael Gillen, David Millson, et al.
Clinical Drug Investigation|December 17, 2020
First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy SubjectsKhalid Abd-Elaziz, Christine Voors-Pette, Kang-Ling Wang, et al.
Neuroscience and Biobehavioral Reviews|August 5, 2022
The role of hypoleptinemia in the psychological and behavioral adaptation to starvation: Implications for anorexia nervosaJohannes Hebebrand, Tom Hildebrandt, Haiko Schlögl, et al.
Trials|January 14, 2010
Alberta Diabetes and Physical Activity Trial (ADAPT): a randomized theory-based efficacy trial for adults with type 2 diabetes--rationale, design, recruitment, evaluation, and disseminationRonald C Plotnikoff, Kerry S Courneya, Ronald J Sigal, et al.
Plos Pathogens|May 30, 2009
Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal traffickingRichard S Mitchell, Chris Katsura, Mark A Skasko, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 1, 2011
A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damageSheng-Jia Zhang, Bettina Buchthal, David Lau, et al.
Journal of Virology|June 6, 2008
Competition model for upregulation of the major histocompatibility complex class II-associated invariant chain by human immunodeficiency virus type 1 NefRichard S Mitchell, Rittik Chaudhuri, O Wolf Lindwasser, et al.
Neurobiology of Disease|November 22, 2023
Activin A targets extrasynaptic NMDA receptors to ameliorate neuronal and behavioral deficits in a mouse model of Huntington diseaseWissam B Nassrallah, Daniel Ramandi, Judy Cheng, et al.
Plos Genetics|August 15, 2009
Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activitySheng-Jia Zhang, Ming Zou, Li Lu, et al.
The Journal of Headache and Pain|November 25, 2025
Uncovering the neurological substrates underlying restlessness in cluster headache - A functional MRI studyShu-Ting Chen, Chia-Chun Chiang, Yung-Lin Chen, et al.
Drugs in R&D|January 8, 2016
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical StudiesPaul Martin, Michael Gillen, David Millson, et al.
Clinical Drug Investigation|December 17, 2020
First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy SubjectsKhalid Abd-Elaziz, Christine Voors-Pette, Kang-Ling Wang, et al.
Neuroscience and Biobehavioral Reviews|August 5, 2022
The role of hypoleptinemia in the psychological and behavioral adaptation to starvation: Implications for anorexia nervosaJohannes Hebebrand, Tom Hildebrandt, Haiko Schlögl, et al.
Trials|January 14, 2010
Alberta Diabetes and Physical Activity Trial (ADAPT): a randomized theory-based efficacy trial for adults with type 2 diabetes--rationale, design, recruitment, evaluation, and disseminationRonald C Plotnikoff, Kerry S Courneya, Ronald J Sigal, et al.
Plos Pathogens|May 30, 2009
Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal traffickingRichard S Mitchell, Chris Katsura, Mark A Skasko, et al.
Pageof 5